- Conditions
- Venous Thromboembolism, Deep Venous Thrombosis, Pulmonary Embolism
- Interventions
- Abelacimab, Apixaban
- Biological · Drug
- Lead sponsor
- Anthos Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 23
- States / cities
- Aurora, Colorado • West Haven, Connecticut • Washington D.C., District of Columbia + 19 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–4
of 4
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Atrial Fibrillation (AF), Stroke
- Interventions
- Abelacimab, Rivaroxaban
- Biological · Drug
- Lead sponsor
- Anthos Therapeutics, Inc.
- Industry
- Eligibility
- 55 Years and older
- Enrollment
- 1,287 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2028
- U.S. locations
- 28
- States / cities
- Huntsville, Alabama • Mobile, Alabama • Stamford, Connecticut + 25 more
- Conditions
- Venous Thromboembolism, Deep Venous Thrombosis, Pulmonary Embolism
- Interventions
- Abelacimab, Dalteparin
- Biological · Drug
- Lead sponsor
- Anthos Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 417 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 10
- States / cities
- Washington D.C., District of Columbia • Evanston, Illinois • St Louis, Missouri + 6 more
- Conditions
- Atrial Fibrillation (AF)
- Interventions
- Abelacimab, Placebo
- Biological · Drug
- Lead sponsor
- Anthos Therapeutics, Inc.
- Industry
- Eligibility
- 65 Years and older
- Enrollment
- 2,500 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 174
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Gilbert, Arizona + 143 more